EDSA: EB05 Reduces Risk of Death 25% in Phase 3 ARDS Trial
On October 28, 2025, Edesa Biotech, Inc. (EDSA) announced positive results from a Phase 3 clinical trial evaluating paridiprubart (EB05) as a...
445 Views
EDSA: EB06 Manufacturing to be Completed by End of 2025
On August 11, 2025, Edesa Biotech, Inc. (EDSA) announced financial results for the third quarter of fiscal year 2025 that ended June 30, 2025 and...
190 Views
EDSA: Advancing EB06 for the Treatment of Vitiligo
On May 14, 2025, Edesa Biotech, Inc. (EDSA) announced financial results for the second quarter of fiscal year 2025 that ended March 31, 2025 and...
296 Views
EDSA: Raises 15 Million to Advance EB06
On February 14, 2024, Edesa Biotech, Inc. (EDSA) announced financial results for the first quarter of fiscal year 2025 that ended December 31,...
324 Views
EDSA: IND Expected in 2025 for EB06 for the Treatment of Vitiligo
On December 13, 2024, Edesa Biotech, Inc. (EDSA) announced financial results for the fourth quarter and full fiscal year 2024 that ended September...
304 Views